VanEck Pharmaceutical ETF $PPH Shares Acquired by UBS Group AG

UBS Group AG boosted its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 145.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,379 shares of the company’s stock after purchasing an additional 63,692 shares during the quarter. UBS Group AG owned approximately 0.94% of VanEck Pharmaceutical ETF worth $11,078,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Sanctuary Advisors LLC boosted its position in VanEck Pharmaceutical ETF by 16.8% during the 4th quarter. Sanctuary Advisors LLC now owns 3,335 shares of the company’s stock valued at $344,000 after purchasing an additional 480 shares during the period. Dunhill Financial LLC boosted its position in VanEck Pharmaceutical ETF by 102.7% during the 4th quarter. Dunhill Financial LLC now owns 4,026 shares of the company’s stock valued at $415,000 after purchasing an additional 2,040 shares during the period. CWM LLC boosted its position in VanEck Pharmaceutical ETF by 36.3% during the 4th quarter. CWM LLC now owns 511 shares of the company’s stock valued at $53,000 after purchasing an additional 136 shares during the period. PFG Investments LLC acquired a new position in VanEck Pharmaceutical ETF during the 4th quarter valued at approximately $249,000. Finally, Farther Finance Advisors LLC boosted its position in VanEck Pharmaceutical ETF by 64.7% during the 4th quarter. Farther Finance Advisors LLC now owns 718 shares of the company’s stock valued at $74,000 after purchasing an additional 282 shares during the period.

VanEck Pharmaceutical ETF Price Performance

NASDAQ:PPH opened at $100.84 on Friday. VanEck Pharmaceutical ETF has a 12-month low of $81.74 and a 12-month high of $112.58. The firm has a market capitalization of $956.97 million, a P/E ratio of 20.21 and a beta of 0.46. The business has a 50 day simple moving average of $102.77 and a 200 day simple moving average of $103.16.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Wednesday, April 1st were paid a dividend of $0.8441 per share. This represents a $3.38 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Wednesday, April 1st. This is an increase from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.